He S Yang1,2, Victoria Costa1,2, Sabrina E Racine-Brzostek1,2, Karen P Acker3, Jim Yee2, Zhengming Chen4, Mohsen Karbaschi5, Robert Zuk5, Sophie Rand1, Ashley Sukhu1, P J Klasse6, Melissa M Cushing1,2, Amy Chadburn1,2, Zhen Zhao1,2. 1. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York. 2. NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, New York. 3. Division of Pediatric Infectious Disease, Weill Cornell Medicine, New York, New York. 4. Department of Population Health Sciences, Weill Cornell Medicine, New York, New York. 5. ET HealthCare, Palo Alto, California. 6. Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York.
Abstract
Importance: Accumulating evidence suggests that children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to manifest mild symptoms and are at a lower risk of developing severe respiratory disease compared with adults. It remains unknown how the immune response in children differs from that of adolescents and adults. Objective: To investigate the association of age with the quantity and quality of SARS-CoV-2 antibody responses. Design, Setting, and Participants: This cross-sectional study used 31 426 SARS-CoV-2 antibody test results from pediatric and adult patients. Data were collected from a New York City hospital from April 9 to August 31, 2020. The semiquantitative immunoglobin (Ig) G levels were compared between 85 pediatric and 3648 adult patients. Further analysis of SARS-CoV-2 antibody profiles was performed on sera from 126 patients aged 1 to 24 years. Main Outcomes and Measures: SARS-CoV-2 antibody positivity rates and IgG levels were evaluated in patients from a wide range of age groups (1-102 years). SARS-CoV-2 IgG level, total antibody (TAb) level, surrogate neutralizing antibody (SNAb) activity, and antibody binding avidity were compared between children (aged 1-10 years), adolescents (aged 11-18 years), and young adults (aged 19-24 years). Results: Among 31 426 antibody test results (19 797 [63.0%] female patients), with 1194 pediatric patients (mean [SD] age, 11.0 [5.3] years) and 30 232 adult patients (mean [SD] age, 49.2 [17.1] years), the seroprevalence in the pediatric (197 [16.5%; 95% CI, 14.4%-18.7%]) and adult (5630 [18.6%; 95% CI, 18.2%-19.1%]) patient populations was similar. The SARS-CoV-2 IgG level showed a negative correlation with age in the pediatric population (r = -0.45, P < .001) and a moderate but positive correlation with age in adults (r = 0.24, P < .001). Patients aged 19 to 30 years exhibited the lowest IgG levels (eg, aged 25-30 years vs 1-10 years: 99 [44-180] relative fluorescence units [RFU] vs 443 [188-851] RFU). In the subset cohort aged 1 to 24 years, IgG, TAb, SNAb and avidity were negatively correlated with age (eg, IgG: r = -0.51; P < .001). Children exhibited higher median (IQR) IgG levels, TAb levels, and SNAb activity compared with adolescents (eg, IgG levels: 473 [233-656] RFU vs 191 [82-349] RFU; P < .001) and young adults (eg, IgG levels: 473 [233-656] RFU vs 85 [38-150] RFU; P < .001). Adolescents also exhibited higher median (IQR) TAb levels, IgG levels, and SNAb activity than young adults (eg, TAb levels: 961 [290-2074] RFU vs 370 [125-697]; P = .006). In addition, children had higher antibody binding avidity compared with young adults, but the difference was not significant. Conclusions and Relevance: The results of this study suggest that SARS-CoV-2 viral specific antibody response profiles are distinct in different age groups. Age-targeted strategies for disease screening and management as well as vaccine development may be warranted.
Importance: Accumulating evidence suggests that children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to manifest mild symptoms and are at a lower risk of developing severe respiratory disease compared with adults. It remains unknown how the immune response in children differs from that of adolescents and adults. Objective: To investigate the association of age with the quantity and quality of SARS-CoV-2 antibody responses. Design, Setting, and Participants: This cross-sectional study used 31 426 SARS-CoV-2 antibody test results from pediatric and adult patients. Data were collected from a New York City hospital from April 9 to August 31, 2020. The semiquantitative immunoglobin (Ig) G levels were compared between 85 pediatric and 3648 adult patients. Further analysis of SARS-CoV-2 antibody profiles was performed on sera from 126 patients aged 1 to 24 years. Main Outcomes and Measures: SARS-CoV-2 antibody positivity rates and IgG levels were evaluated in patients from a wide range of age groups (1-102 years). SARS-CoV-2 IgG level, total antibody (TAb) level, surrogate neutralizing antibody (SNAb) activity, and antibody binding avidity were compared between children (aged 1-10 years), adolescents (aged 11-18 years), and young adults (aged 19-24 years). Results: Among 31 426 antibody test results (19 797 [63.0%] female patients), with 1194 pediatric patients (mean [SD] age, 11.0 [5.3] years) and 30 232 adult patients (mean [SD] age, 49.2 [17.1] years), the seroprevalence in the pediatric (197 [16.5%; 95% CI, 14.4%-18.7%]) and adult (5630 [18.6%; 95% CI, 18.2%-19.1%]) patient populations was similar. The SARS-CoV-2 IgG level showed a negative correlation with age in the pediatric population (r = -0.45, P < .001) and a moderate but positive correlation with age in adults (r = 0.24, P < .001). Patients aged 19 to 30 years exhibited the lowest IgG levels (eg, aged 25-30 years vs 1-10 years: 99 [44-180] relative fluorescence units [RFU] vs 443 [188-851] RFU). In the subset cohort aged 1 to 24 years, IgG, TAb, SNAb and avidity were negatively correlated with age (eg, IgG: r = -0.51; P < .001). Children exhibited higher median (IQR) IgG levels, TAb levels, and SNAb activity compared with adolescents (eg, IgG levels: 473 [233-656] RFU vs 191 [82-349] RFU; P < .001) and young adults (eg, IgG levels: 473 [233-656] RFU vs 85 [38-150] RFU; P < .001). Adolescents also exhibited higher median (IQR) TAb levels, IgG levels, and SNAb activity than young adults (eg, TAb levels: 961 [290-2074] RFU vs 370 [125-697]; P = .006). In addition, children had higher antibody binding avidity compared with young adults, but the difference was not significant. Conclusions and Relevance: The results of this study suggest that SARS-CoV-2 viral specific antibody response profiles are distinct in different age groups. Age-targeted strategies for disease screening and management as well as vaccine development may be warranted.
Authors: Rebecca L Laws; Rebecca J Chancey; Elizabeth M Rabold; Victoria T Chu; Nathaniel M Lewis; Mark Fajans; Hannah E Reses; Lindsey M Duca; Patrick Dawson; Erin E Conners; Radhika Gharpure; Sherry Yin; Sean Buono; Mary Pomeroy; Anna R Yousaf; Daniel Owusu; Ashutosh Wadhwa; Eric Pevzner; Katherine A Battey; Henry Njuguna; Victoria L Fields; Phillip Salvatore; Michelle O'Hegarty; Jeni Vuong; Christopher J Gregory; Michelle Banks; Jared Rispens; Elizabeth Dietrich; Perrine Marcenac; Almea Matanock; Ian Pray; Ryan Westergaard; Trivikram Dasu; Sanjib Bhattacharyya; Ann Christiansen; Lindsey Page; Angela Dunn; Robyn Atkinson-Dunn; Kim Christensen; Tair Kiphibane; Sarah Willardson; Garrett Fox; Dongni Ye; Scott A Nabity; Alison Binder; Brandi D Freeman; Sandra Lester; Lisa Mills; Natalie Thornburg; Aron J Hall; Alicia M Fry; Jacqueline E Tate; Cuc H Tran; Hannah L Kirking Journal: Pediatrics Date: 2020-10-08 Impact factor: 7.124
Authors: A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal Journal: Clin Exp Immunol Date: 2007-11-15 Impact factor: 4.330
Authors: He S Yang; Sabrina E Racine-Brzostek; Mohsen Karbaschi; Jim Yee; Alicia Dillard; Peter A D Steel; William T Lee; Kathleen A McDonough; Yuqing Qiu; Thomas J Ketas; Erik Francomano; P J Klasse; Layla Hatem; Lars Westblade; Heng Wu; Haode Chen; Robert Zuk; Hong Tan; Roxanne C Girardin; Alan P Dupuis; Anne F Payne; John P Moore; Melissa M Cushing; Amy Chadburn; Zhen Zhao Journal: Biosens Bioelectron Date: 2021-01-20 Impact factor: 12.545
Authors: Stuart P Weisberg; Thomas J Connors; Yun Zhu; Matthew R Baldwin; Wen-Hsuan Lin; Sandeep Wontakal; Peter A Szabo; Steven B Wells; Pranay Dogra; Joshua Gray; Emma Idzikowski; Debora Stelitano; Francesca T Bovier; Julia Davis-Porada; Rei Matsumoto; Maya Meimei Li Poon; Michael Chait; Cyrille Mathieu; Branka Horvat; Didier Decimo; Krystalyn E Hudson; Flavia Dei Zotti; Zachary C Bitan; Francesca La Carpia; Stephen A Ferrara; Emily Mace; Joshua Milner; Anne Moscona; Eldad Hod; Matteo Porotto; Donna L Farber Journal: Nat Immunol Date: 2020-11-05 Impact factor: 25.606
Authors: Anna Y Popova; Omor T Kasymov; Vyacheslav Y Smolenski; Vyacheslav S Smirnov; Svetlana A Egorova; Zuridin S Nurmatov; Anzhelika M Milichkina; Gulmira S Suranbaeva; Tatiana E Kuchuk; Irina V Khamitova; Elena V Zueva; Valery A Ivanov; Zhanylai N Nuridinova; Aisuluu A Derkenbaeva; Victoria G Drobyshevskaya; Gulsun Z Sattarova; Marat T Kaliev; Alexandra V Gubanova; Oyuna B Zhimbaeva; Alexandra P Razumovskaya; Vyacheslav N Verbov; Ivan V Likhachev; Alexey V Krasnov; Areg A Totolian Journal: Med Microbiol Immunol Date: 2022-07-02 Impact factor: 4.148
Authors: Costanza Di Chiara; Anna Cantarutti; Paola Costenaro; Daniele Donà; Francesco Bonfante; Chiara Cosma; Martina Ferrarese; Sandra Cozzani; Maria Raffaella Petrara; Francesco Carmona; Cecilia Liberati; Paolo Palma; Giovanni Di Salvo; Anita De Rossi; Mario Plebani; Andrea Padoan; Carlo Giaquinto Journal: JAMA Netw Open Date: 2022-07-01
Authors: Bo Zhai; Karen Clarke; David L Bauer; Krissy K Moehling Geffel; Saran Kupul; Lucas J Schratz; M Patricia Nowalk; Anita K McElroy; James B McLachlan; Richard K Zimmerman; John F Alcorn Journal: J Immunol Date: 2022-03-23 Impact factor: 5.422
Authors: Hugo Perazzo; Sandra W Cardoso; Maria Pia D Ribeiro; Rodrigo Moreira; Lara E Coelho; Emilia M Jalil; André Miguel Japiassú; Elias Pimentel Gouvêa; Estevão Portela Nunes; Hugo Boechat Andrade; Luciano Barros Gouvêa; Marcel Treptow Ferreira; Pedro Mendes de Azambuja Rodrigues; Ronaldo Moreira; Kim Geraldo; Lucilene Freitas; Vinicius V Pacheco; Esau Custódio João; Trevon Fuller; Verônica Diniz Rocha; Ceuci de Lima Xavier Nunes; Tâmara Newman Lobato Souza; Ana Luiza Castro Conde Toscano; Alexandre Vargas Schwarzbold; Helena Carolina Noal; Gustavo de Araujo Pinto; Paula Macedo de Oliveira Lemos; Carla Santos; Fernanda Carvalho de Queiroz Mello; Valdilea G Veloso; Beatriz Grinsztejn Journal: Lancet Reg Health Am Date: 2022-04-12
Authors: Alexandr Zurochka; Maria Dobrinina; Vladimir Zurochka; Desheng Hu; Alexandr Solovyev; Liana Ryabova; Igor Kritsky; Roman Ibragimov; Alexey Sarapultsev Journal: Vaccines (Basel) Date: 2021-06-09